Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
178 participants
INTERVENTIONAL
2021-12-03
2023-10-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of a New Compression System URGO BD001 in the Treatment of VLU (FREEDOM)
NCT04613687
Efficacy and Safety of Light Compression System in the Local Treatment of Mixed Leg Ulcers (PROMETHEE Clinical Investigation)
NCT06899919
Assessment of Efficacy & Tolerance of Urgo 310 3166 Dressing in Local Venous or Mixed Leg Ulcers
NCT03126396
Evaluation of the Efficacy of Multilayer Compression & UrgoStart Plus
NCT06007703
Compression Device Versus 4-layer Compression System
NCT00821431
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study is carried out in around 55 French investigational centers. A total of 178 patients meeting the eligibility criteria will be included. The patients will be followed for 12 weeks and a total of 5 clinical evaluations will be carried out by the investigating centers.
A planimetric survey of the studied VLU is carried out during the initial assessment of the wound (Day 0) and at each assessment provided for in the protocol (Week 2, Week 4, Week 8 and Week 12).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
URGO BD001
Treatment with URGO DB001 during 12-week treament period (5 medical visits are planned: D0, W2, W4, W8, W12)
Venous compression system of the lower limbs stage C6 / C6r of the CEAP classification
Etiological treatment of venous disease of the lower limbs stage C6 / C6r
Kit Biflex
Treatment with Kit Biflex during 12-week treament period (5 medical visits are planned: D0, W2, W4, W8, W12
Venous compression system of the lower limbs stage C6 / C6r of the CEAP classification
Etiological treatment of venous disease of the lower limbs stage C6 / C6r
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Venous compression system of the lower limbs stage C6 / C6r of the CEAP classification
Etiological treatment of venous disease of the lower limbs stage C6 / C6r
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient affiliated to a social security scheme
* Patient agreeing to wear the study compression system daily
* Patient with an ankle circumference between 18 and 25 cm
* Target wound: stage C6 / C6r leg ulcer of the CEAP classification with a 0.8≤ ABPI≤1.3
* Target wound with an area between 1 and 20 cm2
* Target wound with age of ≤24 months
Criteria exclusion:
* Patient with a systemic infection not controlled by appropriate antibiotic therapy
* Patient having presented in the 3 months preceding his inclusion, a deep vein thrombosis
* Patient with advanced stage II or stage III lymphoedema
* Patient bedridden or spending less than an hour per day standing
* Clinically infected target wound
* Cancerized target wound
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Laboratoires URGO
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Patricia Dr SENET, MD
Role: PRINCIPAL_INVESTIGATOR
Hôpitaux Universitaires Paris Est (AP-HP) - Hopital TENON
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Patricia SENET
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ID RCB : 2021-A01874-37
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.